3-(N-hydroxyacetamido)-1-(3,4-dichlorophenyl)propylphosphonic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(N-hydroxyacetamido)-1-(3,4-dichlorophenyl)propylphosphonic acid
• 英文别名: [3-[Acetyl(hydroxy)amino]-1-(3,4-dichlorophenyl)propyl]phosphonic acid
• 化学式: C₁₁H₁₄Cl₂NO₅P
• 分子量: 342.116
• InChiKey: ABGCTQYLJZGMBM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  98.1
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3,4-二氯碘苯 在 palladium diacetate 、 palladium on activated charcoal 盐酸 、 三甲基溴硅烷 、 potassium chloride 、 氢气 、 四丁基醋酸铵 、 sodium cyanoborohydride 、 potassium carbonate 、 三乙胺 作用下， 以 吡啶 、 甲醇 、 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 32.5h， 生成 3-(N-hydroxyacetamido)-1-(3,4-dichlorophenyl)propylphosphonic acid
  参考文献：
  名称：

  α-芳基取代和构象限制性磷米霉素类似物作为有前景的抗疟药的合成

  摘要：

  Fosmidomycin 是一种新型抗疟药，通过抑制 1-脱氧-D-木酮糖 5-磷酸还原异构酶（一种非甲羟戊酸类异戊二烯生物合成途径的必需酶）起作用。这项工作描述了一系列 α-芳基取代的磷米霉素类似物的合成，这些类似物表现出改善的抗疟活性。涉及 3-芳基-3-磷酰基丙醛中间体的线性合成路​​线证明可用于制备这些衍生物。环戊-2-烯酮的磷-迈克尔加成获得了构象受限的类似物。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2006)

  DOI：

  10.1002/ejoc.200600202

文献信息

• Synthesis of α-substituted fosmidomycin analogues as highly potent Plasmodium falciparum growth inhibitors
  作者：Timothy Haemers、Jochen Wiesner、Sara Van Poecke、Jan Goeman、Dajana Henschker、Edwald Beck、Hassan Jomaa、Serge Van Calenbergh

  DOI：10.1016/j.bmcl.2005.12.082

  日期：2006.4

  In view of the promising antimalarial activity of fosmidomycin or its N-acetyl homologue FR900098, the objective of this work was to investigate the influence of aromatic substituents in the alpha-position of the phosphonate moiety. The envisaged analogues were prepared using a linear route involving a 3-aryl-3-phosphoryl propanal intermediate. The activities of all compounds were evaluated on Eschericia

  鉴于磷霉素或其N-乙酰基同系物FR900098的有希望的抗疟活性，这项工作的目的是研究膦酸酯部分α-位上芳族取代基的影响。所设想的类似物是使用涉及3-芳基-3-磷酰基丙醛中间体的线性路线制备的。在大肠杆菌1-脱氧-d-木酮糖5-磷酸还原异构酶和两种恶性疟原虫菌株上评估了所有化合物的活性。与磷霉素相比，几种类似物显示出对恶性疟原虫菌株增强的活性。在磷霉素的α-位具有3,4-二氯苯基取代的化合物1e成为该系列最有效的类似物。抑制恶性疟原虫生长的效力是FR900098的三倍，
• Organophosphoric Derivatives Useful as Anti-Parasitic Agents
  申请人：Van Calenbergh Serge

  公开号：US20080312190A1

  公开（公告）日：2008-12-18

  The present invention relates to novel phosphonic acid compounds having the structural formula (I): wherein: (a) R is a group of 1 to 5 substituents independently selected from the group consisting of fluoro, chloro, bromo, C 1-4 alkoxy, C 1-4 alkyl, hydroxy, formyl, trifluoromethoxy, phenyl, heterocyclic, heterocyclic-substituted methyl, aminomethyl, hydroxy methyl, bromomethyl, sulfonyl chloride, acetyl chloride, nitroso and cyano, (b) R 1 is selected from the group consisting of hydrogen, C 1-7 alkyl, C 3-10 cycloalkyl, aryl, arylalkyl and heterocyclic, and (c) R 2 is selected from the group consisting of hydroxy and hydroxy-protecting groups, and stereoisomer, solvates and salts thereof. These compounds are useful as anti-infectious and anti-parasitic agents, in particular anti-malaria agents.

  本发明涉及具有结构式(I)的新型膦酸化合物，其中：(a) R是1至5个取代基的基团，这些取代基独立地选自于氟、氯、溴、C1-4烷氧基、C1-4烷基、羟基、甲酰基、三氟甲氧基、苯基、杂环、杂环取代的甲基、氨甲基、羟甲基、溴甲基、磺酰氯、乙酰氯、亚硝基和氰基；(b) R1选自于氢、C1-7烷基、C3-10环烷基、芳基、芳基烷基和杂环；(c) R2选自于羟基和羟基保护基团，以及其立体异构体、溶剂化物和盐。这些化合物可用作抗感染和抗寄生虫剂，特别是抗疟疾剂。
• NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY
  申请人：Song Yongcheng

  公开号：US20130065857A1

  公开（公告）日：2013-03-14

  The present invention generally concerns particular methods and compositions for antimicrobial therapy. In particular embodiments, the compositions target DXR. In specific embodiments, the compositions are electron-deficient heterocyclic rings.

  本发明通常涉及特定的抗微生物治疗方法和组合物。在特定实施例中，该组合物针对DXR。在具体实施例中，该组合物是电子不足的杂环环。
• Design, Synthesis, and X-ray Crystallographic Studies of α-Aryl Substituted Fosmidomycin Analogues as Inhibitors of<i>Mycobacterium tuberculosis</i>1-Deoxy-<scp>d</scp>-xylulose 5-Phosphate Reductoisomerase
  作者：Mounir Andaloussi、Lena M. Henriksson、Anna Wiȩckowska、Martin Lindh、Christofer Björkelid、Anna M. Larsson、Surisetti Suresh、Harini Iyer、Bachally R. Srinivasa、Terese Bergfors、Torsten Unge、Sherry L. Mowbray、Mats Larhed、T. Alwyn Jones、Anders Karlén

  DOI：10.1021/jm2000085

  日期：2011.7.28

  The natural antibiotic fosmidomycin acts via inhibition of 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXR), an essential enzyme in the non-mevalonate pathway of isoprenoid biosynthesis. Fosmidomycin is active on Mycobacterium tuberculosis DXR (MtDXR), but it lacks antibacterial activity probably because of poor uptake. alpha-Aryl substituted fosmidomycin analogues have more favorable physicochemical properties and are also more active in inhibiting malaria parasite growth. We have solved crystal structures of MtDXR in complex with 3,4-dichlorophenyl substituted fosmidomycin analogues; these show important differences compared to our previously described forsmidomycin-DXR complex. Our best inhibitor has an IC50 = 0.15 mu M on MtDXR but still lacked activity in a mycobacterial growth assay (MIC > 32 mu g/mL). The combined results, however, provide insights into how DXR accommodates the new inhibitors and serve as an excellent starting point for the design of other novel and more potent inhibitors, particularly against pathogens where uptake is less of a problem, such as the malaria parasite.
• US7638505B2
  申请人：——

  公开号：US7638505B2

  公开（公告）日：2009-12-29